Buy BPC-157 + TB-500 Blend 10 mg in Australia
For laboratories and researchers in Australia, the BPC-157 + TB-500 Blend 10 mg vial costs $109.99 from Australian Research Peptides, though it is out of stock for now. The vial holds lyophilised powder covering both chains together. BPC-157 is a fifteen-amino-acid chain, GEPPPGKPADDAGLV, which laboratory tests link to VEGFR2, the receptor that drives new blood-vessel growth; TB-500 is Ac-LKKTETQ, the seven-amino-acid piece of thymosin beta-4 that grips actin. Both are studied in cell-signalling research, and the blend reaches every state and territory by post. In vitro research purposes only.
Cell Signalling Research · Lyophilised Powder · Independently lab-tested · SKU 40519
$109.99
Presentation
10 mg per vial
Grade
Research Grade
Form
Lyophilised Powder
Category
Cell Signalling Research
Currently out of stock — stocked lines dispatch same business day before 12pm Sydney time, Mon–Fri
Tracked shipping Australia-wide ·typically 1–2 business days to most areas by Express Post · free post over $199, free Express over $299
Batch certificates — published in the COA library
For in vitro research purposes only. Not for human consumption. Not for animal consumption. This product is not a drug, food, cosmetic, or dietary supplement. ARP gives no usage, medical or therapeutic guidance of its own.
BPC-157 + TB-500 · 10 mg
$109.99
What we do have in stock
BPC-157 + TB-500 is out of stock and we have not put a substitute in its place. These ship from our shelf in Australia today.
Browse all Cell Signalling Research
About BPC-157 + TB-500
Both halves of this vial come from the preclinical cell-signalling literature. Putting them in one vial is a packaging choice, not a research finding — nothing published establishes that the pair does more than either chain on its own. The quantity on this listing is the total for the vial, covering both peptides at once.
The powder is freeze-dried and holds two chains of very unequal length. BPC-157 runs to fifteen amino acids, sequence GEPPPGKPADDAGLV. TB-500 is seven, Ac-LKKTETQ, matching residues 17 to 23 of thymosin beta-4 with an acetyl cap on one end. Thymosin beta-4 itself is 43 amino acids long, so TB-500 is a small piece of it rather than the whole protein. ARP lists each peptide on its own as well, and the pair is written BPC157 and TB500 as often as it is written with hyphens.
The two are studied down different routes. Laboratory work on BPC-157 links it to VEGFR2, the vascular endothelial growth factor receptor 2. The LKKTETQ stretch in TB-500 is thymosin beta-4's actin-binding motif, and actin is the protein cells use to build their internal scaffolding. Whether the two converge on shared downstream pathways is an open question in the literature rather than an established one.
BAC water (bacteriostatic water) is also in our range.
The peptide calculator works out the mg/mL concentration of a reconstituted vial.
What is in the vial
| Component | Amount per vial |
|---|---|
| BPC-157 | ~5 mg |
| TB-500 — a fragment corresponding to the actin-binding region of thymosin beta-4 — not the full protein | ~5 mg |
| Total | 10 mg per vial |
BPC-157 + TB-500 specifications, storage and shipping
- Compound: BPC-157 + TB-500
- Also known as: BPC-157 with TB-500 (thymosin beta-4 fragment)
- Class: Two-peptide blend: a pentadecapeptide with an actin-binding thymosin beta-4 fragment
- Appearance: White to off-white lyophilised powder
- Sizes & SKUs: 10 mg (40519)
- Presentation: sealed glass vial
- Form: Lyophilised Powder
- Grade: Research grade
- Testing: Independently lab-tested for identity and amount before release — the laboratory's report for this blend gives a measured amount for each peptide and no purity figure
- Identity confirmation: Mass spectrometry
- Certificates: issued by Janoshik, an independent laboratory, and published in the COA library
- Classification: In vitro research purposes only — laboratory reference material
- Lyophilised — long term
- −20 °C to −80 °C — long-term storage
- Lyophilised — short term
- 2–8 °C — refrigerated, for a few months
- Reconstituted
- 2–8 °C — use within 8–12 weeks
BPC-157 + TB-500 is independently lab-tested for identity and amount. The full laboratory report is published in the COA library. BPC-157 + TB-500 is tested by Janoshik, an independent laboratory, commissioned by the manufacturer rather than by Australian Research Peptides.
- BPC-157 + TB-500 10 mg: measured content BPC-157 6.54 mg · TB-500 5.76 mg · laboratory batch 2026-06 · analysed 23 June 2026
This line is currently out of stock. Stocked lines ordered before 12pm Sydney time on a business day are dispatched the same day with tracked shipping. Standard delivery within Australia typically takes 2–5 business days. See Shipping & Delivery for details, and follow your parcel on the Track Order page.
For in vitro research purposes only. Not for human consumption. Not for animal consumption. Not a drug, food, cosmetic, or dietary supplement. No therapeutic or medical claims are made.
Questions about BPC-157 + TB-500
This question guide from Australian Research Peptides covers BPC-157 + TB-500 in Australia: what the listing contains, live buying and delivery questions, research context, handling, testing and comparisons. Start with the quick answers, then open the topic group that matches your search.
Buying, price and availability
BPC-157 + TB-500 comes from Australian Research Peptides, which posts from inside Australia, so an order travels internally and never queues at customs. One vial carries both chains — fifteen residues and seven — under the single product code BPCTB, with no strength to choose. Search terms bpc tb, bpc 157 tb 500 and tb500 bpc all reach the same ARP product record. Express delivery reaches every territory and state.
A BPC-157 + TB-500 order arrives 1–2 business days after lodgement in Canberra, Sydney, Melbourne and Adelaide by Express Post, 1–3 in Brisbane, 2–4 in Perth and Darwin, and 2–5 anywhere by standard tracked post. Because both peptides sit in one vial it travels as a single small parcel rather than two, and adding other items does not split it.
A BPC-157 + TB-500 vial needs less preparation than two separate vials, because it is one reconstitution and one diluent volume where two vials would be two of each. The ratio between the two peptides is fixed when the blend is made, so it cannot be adjusted at the bench, and the vial holds those peptides only.
BPC-157 + TB-500 is banned in sport on both counts, under different headings. BPC-157 falls in S0 because no regulator has approved it; thymosin beta-4 and TB-500 sit with the growth factors in section S2. Neither heading eases outside the competition season. Sport Integrity Australia tests Australian athletes, and a finding follows from the substance being present.
Identity, names and exact format
BPC-157 + TB-500 is two names joined, not one compound's name. BPC-157 is a laboratory code, and the 157 marks one particular fifteen-amino-acid sequence. TB stands for thymosin beta, because TB-500 is a fragment of thymosin beta-4. What the number 500 refers to is not established in the sources reviewed, so this answer does not guess at it.
Spelt without hyphens, BPC157 and TB500 name the two peptides Australian Research Peptides dries into one 10 mg blend vial and lists as BPC-157 + TB-500. Laboratories and researchers reach the same record whichever spacing they type. Each peptide is also catalogued on its own, so the pair can be ordered blended or as two single-compound vials.
No. BPC-157 and TB-500 hold no approval from any medicines regulator, and Australian Research Peptides lists this vial for in vitro research purposes only — nothing on this website is medical, therapeutic or usage advice. What can be checked about the material is chemical: the blend is independently lab-tested, and its published certificate records the identity and measured amount of each peptide.
One blended vial costs less than the two single vials it replaces, and Australian Research Peptides publishes a current price for all three lines so the comparison can be made directly. The trade is control: a blend fixes the ratio between the two peptides, so the two cannot be varied independently. Buy them separately when the ratio matters, and blended when it does not.
Research context and evidence
BPC-157 + TB-500 is one vial containing two research peptides, freeze-dried into a single cake. The BPC-157 half runs to fifteen amino acids and was first described in gastric juice. The TB-500 half is a seven-amino-acid piece of thymosin beta-4, a protein involved in how cells organise actin. Both appear in preclinical cell-migration studies.
BPC-157 + TB-500 puts two separate molecules in one vial, each with its own binding target. BPC-157 is a fifteen-residue sequence, GEPPPGKPADDAGLV, associated in laboratory work with VEGFR2, a vascular endothelial growth factor receptor (Hsieh 2017). TB-500 carries the LKKTETQ motif, the seven-residue stretch of thymosin beta-4 that binds actin, a cytoskeletal structural protein (Philp 2003). Both molecules are studied in cell-signalling research.
BPC-157 + TB-500 sits in cell-signalling research, where both molecules are studied in the laboratory and nowhere beyond it. BPC-157 is the fifteen-amino-acid sequence GEPPPGKPADDAGLV; TB-500 is Ac-LKKTETQ, a seven-amino-acid piece of thymosin beta-4 with an acetyl group capping one end. Australian Research Peptides dries the pair into one 10 mg vial and supplies it for in vitro research purposes only.
BPC-157 + TB-500 holds twenty-two amino acids, split across two separate molecules. BPC-157 contributes fifteen and TB-500 contributes seven. They stay two chains in the vial, so this is not one twenty-two-residue peptide. The acetyl group capping TB-500 counts as a chemical modification, not an extra amino acid. The sequences are GEPPPGKPADDAGLV and Ac-LKKTETQ.
TB-500 is not the same as thymosin beta-4. The TB-500 half of this vial is a fragment rather than the whole protein. Thymosin beta-4 has 43 amino acids (UniProt); TB-500 copies seven of them, residues 17 to 23, which is the stretch that binds actin. An acetyl cap sits on its front end. Suppliers often use both names loosely, so check which molecule a competing listing actually means.
A BPC-157 + TB-500 vial from Australian Research Peptides holds 10 mg in total, blended at the standard 1:1 ratio, so it is about 5 mg of each peptide. Those are nominal formulation figures. When an exact-strength batch document is published, its laboratory-measured amount for each chain takes precedence over the nominal formulation figures. Compare the vial against another blend rather than against a single-compound vial, or you are comparing different things.
BPC-157 + TB-500 exists for convenience, and it makes no research claim. The vial dries both peptides into one cake instead of two. Australian Research Peptides also lists each of them on its own, so you can order them apart if you prefer. Blending fixes the ratio between the two chains; separate vials leave that ratio free.
Reconstitute BPC-157 + TB-500 by running a suitable diluent gently against the glass, never straight onto the powder. Both peptides dissolve into the same liquid, so one addition serves the whole vial. Swirl rather than shaking. Dissolving can take minutes and occasionally hours. Bachem advises aliquoting peptide solutions and keeping them frozen below −15 °C rather than storing one volume long term.
Handling, storage and measurements
Dissolved BPC-157 + TB-500 gets the 8–12 week refrigerated life Australian Research Peptides prints against every peptide line it carries, but a blend truly lasts only as long as whichever chain fails first. Bachem lists glutamine among the residues that limit a dissolved peptide, and the TB-500 component finishes on exactly that. Nothing lets a researcher discard one chain and keep the other.
A BPC-157 + TB-500 vial holds 10 mg in total across both peptides, so anything the diluent does applies to the pair together and never to one of them alone. Australian Research Peptides blends that 10 mg at roughly 5 mg of each. No fill volume is published for the vial, and the ratio between the two compounds is fixed when it is blended rather than at the bench.
BPC-157 + TB-500 clears more slowly than a single peptide, because its two components do not dissolve at matching speeds, so a brief cloudy phase while one chain is still going in is ordinary. Bubbles raised by over-enthusiastic handling add to the effect. Stand the vial upright and look again ten minutes later. Opacity that lingers, or grit settling out afterwards, signals something has degraded.
BPC-157 + TB-500 arrives dry, with no liquid in the vial, so laboratory work needs a diluent first, usually an aqueous one. A diluent is the liquid a powder is dissolved in, and one volume of it serves both peptides, since both chains dissolve into that same volume.
Australian Research Peptides supplies the BPC-157 + TB-500 blend — the blend is unavailable at the moment, and weekday orders before 12pm Sydney time are lodged on the day they arrive once it returns. ARP is an Australian company posting to laboratories and researchers from Sydney, under Cell Signalling Research alongside each peptide sold separately. The blend is independently lab-tested for identity and amount. Bank transfer and PayID are the accepted payment methods.
Australian Research Peptides charges one Australian-dollar figure for the whole BPC-157 + TB-500 vial, not two amounts for two peptides. The number quoted is read from the live catalogue entry, so it moves when the business reprices rather than going stale in prose. The vial is blended at about 5 mg of each peptide, so the price buys both together rather than either one on its own. A second vial is charged at the same figure as the first. Delivery is charged on top.
Two vials of the blend clear the free Standard tracked post threshold, though without much room; one alone does not. Express Post is waived only at a higher figure that a two-vial order does not reach, so choosing Express still attracts a fee. Qualification is judged on the goods subtotal before any discount code comes off, so using a code can never cost you the free post.
Ordering BPC-157 + TB-500 means dealing with Australian Research Peptides directly, online rather than through a marketplace or a pharmacy. The blend vial holds the two peptides and nothing else. Two payment methods are accepted, Australian bank transfer and PayID, and each is sent from the buyer's own bank. Confirmation carries an order reference and the account particulars to pay into.
Testing and batch documents
The BPC-157 + TB-500 blend is stocked by Australian Research Peptides and by no Australian pharmacy, Chemist Warehouse included. Neither peptide is registered as a medicine here, and a combination of two unregistered compounds cannot be dispensed under any authorisation a retailer holds. ARP dries the pair into one 10 mg research vial.
Ordering, payment and Australian delivery
Yes, and a BPC-157 + TB-500 vial trips people up for a specific reason: the ten-milligram figure covers both chains together rather than each separately, so combining two peptides does not double what is visible. What dries down is one thin cake of shared solid, frequently hard to tell apart from clean glass. Two compounds in a single container means two chemistries, never twice the bulk.
Neither half of the BPC-157 + TB-500 blend carries a marketing authorisation, in the United States or anywhere else, so the pairing cannot be approved either. Thymosin beta-4 never produced a licensed product, and no agency has ever reviewed BPC-157 for approval as a medicine. Two unapproved compounds sharing one vial do not inherit approval from somewhere.
Yes — BPC-157 + TB-500 is independently lab-tested for identity and amount at an outside laboratory, engaged by the manufacturer rather than by ARP. The report names both peptides, a fifteen-residue chain and a seven-residue chain, and gives a measured milligram figure for each; it states no purity figure. The blend also has a record in ARP's CoA library, findable by product name. The library shows each product and strength as published or still to come.
BPC-157 + TB-500 has no scientific synonym of its own because it contains two peptides: BPC-157, also recorded as bepecin or PL 14736, and TB-500, the acetylated thymosin beta-4 fragment 17-23. Australian Research Peptides uses BPCTB as the catalogue code for this blend.
Access and regulatory questions
BPC-157 + TB-500 is not the same as the GLOW listing. GLOW is a three-peptide vial, while BPC-157 + TB-500 holds two. The extra compound in GLOW is GHK-Cu, a copper-binding chain of three amino acids. GLOW's total quantity per vial differs as well, so the two numbers are not comparable. Australian Research Peptides sells them as separate products; compare the compound names and quantities before treating them as interchangeable.
The BPC-157 + TB-500 vial holds two peptides. GLOW adds GHK-Cu to the same two, making three, and KLOW adds both GHK-Cu and KPV, making four. So the pair is the base, GLOW is that base plus a copper tripeptide, and KLOW is the widest of the three. All are Australian Research Peptides listings and all are single vials.
Combining the BPC-157 + TB-500 blend with GHK-Cu produces the same three peptides that Australian Research Peptides’ GLOW vial already contains, so the simpler route is the GLOW listing rather than two vials. Buying them separately makes sense only if you want to vary the GHK-Cu independently, since GLOW fixes the ratio.
Check what a supplier actually publishes: the independent laboratory's own report rather than figures retyped into a product listing, and, for a blend, the identity and measured amount of each peptide. Australian Research Peptides publishes that report for this blend; as a two-peptide blend it carries no single purity figure. Stock is held here and dispatched from Sydney, so no vial crosses a border.